维奈克拉联合剂量调整的 R-EPOCH（VR-DA-EPOCH）或 G-EPOCH 桥接后续细胞治疗转化型淋巴瘤患者：单中心临床经验

Indolent lymphoma, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL), can undergo histological transformation into an aggressive subtype, typically diffuse large B-cell lymphoma (DLBCL). The prognosis of transformed lymphoma is poor. In this study, we reported the efficacy and toxicity of a combination of venetoclax, dose-adjusted rituximab or obinutuzumab, etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide (VR-DA-EPOCH or VG-DA-EPOCH) in 11 patients with biopsy-proven histology transformation into DLBCL, including 8 patients with RT and 3 with transformed FL (tFL). The study was conducted between October 2019 and March 2023 at our single center.

The median age of participants at enrolment was 53 years. Six patients (85. 7%, 6/7) achieved complete remission (CR) at the end of treatment. The best overall response rate (ORR) and CR rate were both 72. 7%, respectively. Two patients received autologous hemopoietic stem cell transplant (ASCT) while two patients received ASCT concurrently with CAR-T therapy for consolidation.

With a median follow-up of 13. 5 (range, 2. 4-29. 8) months after enrollment, the median event-free survival, progression-free survival, and overall survival were 9. 4, 11. 5, and 17. 5 months, respectively. Hematologic toxicities of grade 3 consisted of neutropenia (90. 9%, 10/11), thrombocytopenia (63. 6%, 7/11), and febrile neutropenia (54. 5%, 6/11).

In conclusion, VR-DA-EPOCH or VG-DA-EPOCH was a promising strategy to achieve an early remission, bridging to cellular therapy within this population.